Innoviva (INVA) Non Operating Investment Income (2020 - 2026)
Innoviva posted quarterly Non Operating Investment Income of $33.6 million for Q1 2026, up 151.42% year-on-year from $13.4 million in Q1 2025, and up 6.55% on a QoQ basis from $31.5 million in Q3 2025.
Innoviva (INVA) has 7 years of Non Operating Investment Income data on file, last reported at $33.6 million in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Investment Income rose 151.42% year-over-year to $33.6 million; the trailing twelve-month figure through Mar 2026 stood at $11.1 million (up 108.77% YoY), and the FY2025 full-year result was $20.2 million, up 134.08% from the prior year.
- Non Operating Investment Income for Q1 2026 stood at $33.6 million, up from $31.5 million in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $33.6 million in Q1 2026 and bottomed at -$65.3 million in Q1 2025.
- The 5-year median for Non Operating Investment Income is -$2.6 million (2023), against an average of -$6.0 million.
- The widest annual swing landed in 2024, when Non Operating Investment Income slumped 36714.46%; it then soared 286.05% in 2025.
- A 5-year view of Non Operating Investment Income shows it stood at -$10.2 million in 2022, then soared by 74.04% to -$2.6 million in 2023, then plunged by 541.52% to -$16.9 million in 2024, then jumped by 286.05% to $31.5 million in 2025, then increased by 6.55% to $33.6 million in 2026.
- The last three Non Operating Investment Income figures came in at $33.6 million (Q1 2026), $31.5 million (Q3 2025), and $11.3 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 235,807.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 230,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn | 33.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 33.58 Mn |
| Mar 31, 2026 | 33.58 Mn |
| Sep 30, 2025 | 31.51 Mn |
| Sep 30, 2025 | 31.51 Mn |
| Jun 30, 2025 | 11.28 Mn |
| Jun 30, 2025 | 11.28 Mn |
| Mar 31, 2025 | -65.30 Mn |
| Mar 31, 2025 | -65.30 Mn |
| Sep 30, 2024 | -16.94 Mn |
| Sep 30, 2024 | -16.94 Mn |
| Jun 30, 2024 | -30.56 Mn |
| Jun 30, 2024 | -30.56 Mn |
| Mar 31, 2024 | -13.34 Mn |
| Mar 31, 2024 | -13.34 Mn |
| Sep 30, 2023 | -2.64 Mn |
| Sep 30, 2023 | -2.64 Mn |
| Jun 30, 2023 | -83,000.00 |
| Jun 30, 2023 | -83,000.00 |
| Mar 31, 2023 | -2.16 Mn |
| Mar 31, 2023 | -2.16 Mn |
| Sep 30, 2022 | -10.17 Mn |
| Sep 30, 2022 | -10.17 Mn |
| Jun 30, 2022 | -15.78 Mn |
| Jun 30, 2022 | -15.78 Mn |
| Mar 31, 2022 | 2.54 Mn |
| Mar 31, 2022 | 2.54 Mn |
| Sep 30, 2021 | 33.61 Mn |
| Sep 30, 2021 | 33.61 Mn |
| Jun 30, 2021 | 45.32 Mn |
| Jun 30, 2021 | 45.32 Mn |
| Mar 31, 2021 | 55.05 Mn |
| Mar 31, 2021 | 55.05 Mn |
| Dec 31, 2020 | -38.48 Mn |
| Dec 31, 2020 | -38.48 Mn |
| Sep 30, 2020 | -29.37 Mn |
| Sep 30, 2020 | -29.37 Mn |
| Jun 30, 2020 | 46.70 Mn |
| Jun 30, 2020 | 46.70 Mn |
| Mar 31, 2020 | 21.92 Mn |
| Mar 31, 2020 | 21.92 Mn |